Evelo Biosciences, Inc. (NASDAQ:EVLO – Get Free Report) saw unusually large options trading on Wednesday. Stock traders acquired 1,885 put options on the company. This represents an increase of approximately 1,101% compared to the average daily volume of 157 put options.
Evelo Biosciences Stock Down 100.0%
Evelo Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00. The firm has a market cap of $2,000.00, a P/E ratio of 0.00 and a beta of 2.03.
Evelo Biosciences Company Profile
Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered immunomodulatory therapies that leverage the gut-body network. The company’s proprietary platform is designed to mimic signals normally generated by gut commensal bacteria to regulate immune function throughout the body. Evelo’s approach focuses on non-live, inactivated microbial derivatives, aiming to offer a new class of biologics that can be administered by mouth and engage mucosal immune pathways to treat a range of diseases.
The company’s pipeline spans inflammatory, autoimmune and oncology indications.
Further Reading
- Five stocks we like better than Evelo Biosciences
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
